Reuters alone with Glaxo prostate drug news

Reuters was alone in reporting on prospects for GlaxoSmithKline’s prostate drug Avodart on April 14. Shares in the world’s second biggest drug maker rose as much as 2.6 percent the next day, outperforming the European pharmaceuticals sector. Glaxo’s head of oncology said in an interview he hoped data due at a medical meeting on April 27 would open up a major new market for the drug in cancer prevention. Several analysts highlighted the potential of Avodart in research notes in the following days.